
via Johns Hopkins University
Antibody injections are a highly desirable treatment for people with chronic diseases such as cancer, psoriasis, Crohn’s disease and arthritis. And recently, antibodies have been in the news as a promising treatment for severe cases of COVID-19.
But the costly, time-consuming manufacturing process to produce antibodies prevents these treatments from being accessible to most patients.
Andrew Zydney, Bayard D. Kunkle Chair and professor of chemical engineering at Penn State, has identified a new method to manufacture antibodies, which could drive down the production cost. His research results were recently published in Biotechnology Progress.
“If you look at the top 10 best-selling medications, by annual sales, eight are in the category of monoclonal antibodies,” Zydney said. “And every year, individuals and insurance companies spend upwards of $100 billion on antibodies, with costs to treat a single patient often exceeding $50,000. There remains a huge unmet need for these products in treating a growing range of diseases.”
Known as precipitation, Zydney’s new protein purification process involves adding zinc chloride and polyethylene glycol, a water-soluble polymer, to a solution containing the antibody. This causes the antibody to precipitate so that the impurities can be washed away.
Though the precipitation process has been used for 70 years in blood plasma processing, it has never been used for the commercial production of antibodies, according to Zydney.
“To precipitate means ‘to come out’ of a solution in a solid form,” he said. “For example, when you put salt in warm water, it dissolves. But if you put a lot of salt into cold water, some of that salt will remain as solid crystals. In the same way, proteins would normally dissolve in a solution, but you can find certain conditions where they come out as solid.”
Zydney explained that the zinc chloride used in precipitation is a simple salt, making it much cheaper than other purification methods. It also saves time, as it is possible to yield large quantities of proteins in short periods of time.
Currently, antibodies are produced using a process called Protein A affinity chromatography, where the antibody binds to Protein A, which is immobilized in a chromatography column. The impurities can be washed away from the bound antibody, after which the pH level is adjusted to recover the purified antibody product. A single Protein A chromatography column can cost more than $10 million.
“That is just one step in the current manufacturing process, and it is what makes antibody manufacturing so expensive,” Zydney said. “All of the major biotechnology companies are big players in this space.”
The precipitation process eliminates the need for the costly chromatography process, as antibodies are purified directly from the solution by filtration through hollow fiber membranes.
“What we do in our research group is relatively small scale,” He said. “But the precipitation process has the potential to be easily scaled up, potentially enabling biopharmaceutical companies to produce lower-cost antibodies for the patients who need them.”
Todd Przybycien, professor of chemical and biological engineering at Rensselaer Polytechnic Institute, contributed to this research.
Original Article: Antibody injections could become more affordable with new production method
More from: Pennsylvania State University | Rensselaer Polytechnic Institute
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibody injections
- Study results show conjugate therapy produced remissions in one-third of patients with drug-resistant ovarian cancer
In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab ...
- With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028
According to Fortune Business Insights, The Monoclonal Antibody Therapy Market size is anticipated to reach USD 451.89 Billion by 2028, the market size was 157.33 Billion in 2020 and is anticipated to ...
- Small study shows promise for antimalarial monoclonal antibody to prevent malaria
Monoclonal antibodies represent a promising approach ... or 10 mg/kg via IV infusions, or by subcutaneous injection (injected just under the skin). Study participants were bitten by five ...
- FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants
In this article The Food and Drug Administration on Thursday pulled its authorization for AstraZeneca 's Evusheld, an antibody injection that people with weak immune systems relied on for ...
- FDA pulls Evusheld authorization as coronavirus evolution quashes another therapy
The Food and Drug Administration on Thursday withdrew the authorization of Evusheld, the latest antibody therapy to be rendered ineffective by the mutations the virus has picked up. Notably ...
Go deeper with Google Headlines on:
Antibody injections
[google_news title=”” keyword=”antibody injections” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antibody manufacturing
- EGFR Antibody Market for the Period 2023 To 2028: With Top Countries Data Analysis and Latest Development Plan
Global EGFR Antibody Market Report ( 86 Pages) provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector. Get a sample PDF of the report at ...
- Know Bispecific Antibody Therapeutic Market 2023 Future Developments with Top Players, Major Regions, Forecast: Research by Market Research Guru
Get a sample PDF of the report at Key player companies in global Bispecific Antibody Therapeutic Market are: The report providing scenario of history and present performance with an overview of ...
- Biocytogen and Hansoh Pharma Announce an Antibody License Agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally.
- Monoclonal Antibody Discovery and Analysis market is projected to grow at a CAGR of 9.0% by 2032: Visiongain Reports Ltd
It includes profiles of Monoclonal Antibody Discovery and Analysis and Forecasts Market Segment by Business Type, (Instruments Manufacturing, Services & Solutions, Ancillary Kits) Market Segment ...
- Monoclonal Antibody Discovery and Analysis market is projected to grow at a CAGR of 9.0% by 2032: Visiongain Reports Ltd
Visiongain has published a new report entitled Monoclonal Antibody Discovery and Analysis 2022-2032. It includes profiles of Monoclonal Antibody Discovery and Analysis and Forecasts Market Segment by ...
Go deeper with Google Headlines on:
Antibody manufacturing
[google_news title=”” keyword=”antibody manufacturing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]